drugset / Trial / NCT00803361

Duloxetine for the Treatment of Generalized Anxiety Disorder

NCT00803361

Phase 3 Completed 210 enrolled Eli Lilly and Company Boehringer Ingelheim · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder

Timeline

Start
2008-12
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral
Subject Duloxetine Small molecule 120 mg Oral